# US 2024/0245783 A1 · Metallo-beta-lactamase inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0245783 A1
- Document ID: US20240245783A1
- Status: Published application
- Kind: A1
- Application number: 18/560,182
- Filed: 2022-05-13
- Published: 2024-07-25
- Earliest claimed: 2021-05-13
- Assignees: National University Corporation Kumamoto University
- Applicants: National University Corporation Kumamoto University
- Inventors: Tomohiro SAWA; Yoshihiro YAMAGUTI; Yoshichika ARAKAWA
- Web page: https://patentgrep.com/patent/US20240245783A1

## CPC

- A61K 47/547: {Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent}
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61P 31/04: Antibacterial agents
- C07D 477/24: with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 6
- C07D 499/68: with aromatic rings as additional substituents on the carbon chain
- C07D 501/28: with the 7-amino radical acylated by an aliphatic carboxylic acid, which is substituted by hetero atoms
- C07D 501/30: with the 7-amino-radical acylated by an araliphatic carboxylic acid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A compound represented by formula (I), formula (II), or formula (IV), or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt thereof, for use in inhibiting metallo-β-lactamases.

## Claims

### Claim 1

A compound represented by formula (I), formula (II), or formula (IV):
or a pharmaceutically acceptable salt thereof, wherein
Q is a direct bond or a group: —N(—R2)—CH(—R1)—C(═O)—, wherein a nitrogen atom of the group is linked to a carbonyl group described in formula (I) or formula (II);
R1 is phenyl optionally substituted with one or more substituents selected from X1, 5- or 6-membered heteroaryl optionally substituted with one or more substituents selected from X1, C1-10 alkyl optionally substituted with one or more substituents selected from X2, C2-10 alkenyl optionally substituted with one or more substituents selected from X2, C2-10 alkynyl optionally substituted with one or more substituents selected from X2, C3-10 cycloalkyl optionally substituted with one or more substituents selected from X2, or C6-10 cycloalkanedienyl optionally substituted with one or more substituents selected from X3;
R2 is a hydrogen atom or C1-6 alkyl;
R3 is a hydrogen atom or C1-6 alkyl;
R4 is a hydrogen atom, C1-6 alkyl optionally substituted with one or more substituents selected from X4, or 5- or 6-membered non-aromatic heterocyclyloxy optionally substituted with one or more substituents selected from X5, wherein the heterocyclyl of the non-aromatic heterocyclyloxy is optionally fused with a benzene ring;
R5 is a hydrogen atom, a halogen atom, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl optionally substituted with R6, or methyl substituted with R7;
R6 is phenyl optionally substituted with one or more substituents selected from X1, or 5- or 6-membered heteroaryl optionally substituted with one or more substituents selected from X1;
R7 is 5- or 6-membered heteroarylsulfanyl optionally substituted with one or more substituents selected from X5, 5 or 6-membered heteroaryloxy optionally substituted with one or more substituents selected from X5, phenylsulfanyl optionally substituted with one or more substituents selected from X5, phenyloxy optionally substituted with one or more substituents selected from X5, (C1-6 alkyl)carbonyloxy, carbamoyloxy, pyridinium-1-yl optionally fused with C5-7 cycloalkyl and optionally substituted with X5, or 1-methylpyrrolidinium-1-yl optionally substituted with X5;
X1 is amino, hydroxy, C1-6 alkyl, C1-6 alkoxy, a halogen atom, or phenyl optionally substituted with one or more halogen atoms or hydroxy;
X2 is amino, hydroxy, C1-6 alkoxy, a halogen atom, carboxy, or (C1-6 alkoxy)carbonyl;
X3 is C1-6 alkyl or a halogen atom;
X4 is (C1-6 alkyl)carbonyloxy or (C1-6 alkoxy)carbonyloxy;
X5 is C1-6 alkyl optionally substituted with R8, or carbamoyl;
X6 is C1-6 alkyl, a halogen atom, (C1-6 alkoxy)carbonyl, or carboxy;
R8 is hydroxy, sulfo, or carboxy;
R9 is a hydrogen atom or methyl;
Ra is a polyamine group represented by any of the following formulae:
and ● indicates the bonding position; and
Rb is selected from a group represented by the following formula:
Q1 is C2-6 alkylene;
R10 is a hydrogen atom, C1-6 alkyl, or —CH═NH;
R11 and R12 are each independently a hydrogen atom or C1-6 alkyl;
R13 is a hydrogen atom, C1-6 alkyl, —CH2NHSO2NH2, or —CONR14R15, wherein the alkyl is optionally substituted with one or more substituents selected from —NR14R15 and hydroxy;
R14 is a hydrogen atom, C1-6 alkyl, or phenyl optionally substituted with one or more substituents selected from X6; and
R15 is a hydrogen atom or C1-6 alkyl.

### Claim 2 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R1 is phenyl optionally substituted with one or more substituents selected from X1, 5- or 6-membered heteroaryl optionally substituted with one or more substituents selected from X1, or C6-10 cycloalkanedienyl optionally substituted with one or more substituents selected from X3.

### Claim 3 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R4 is a hydrogen atom or C1-6 alkyl substituted with one substituent selected from X4.

### Claim 4 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein Ra is a polyamine group represented by formula IIIa, formula IIIh or formula IIIi.

### Claim 5 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R2 is a hydrogen atom.

### Claim 6 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is represented by formula II.

### Claim 7 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R5 is a hydrogen atom, a halogen atom, C1-6 alkyl, C1-6 alkoxy, or C2-6 alkenyl.

### Claim 8 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein Rb is selected from a group represented by the following formula:

### Claim 9 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein Rb is selected from a group represented by the following formula:

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, for use in treating an infectious disease caused by a β-lactam antibiotic-resistant bacterium.

### Claim 12 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the resistant bacterium is a metallo-β-lactamase-expressing bacterium.

### Claim 13 (depends on 10)

The pharmaceutical composition according to claim 10, for use in combination with a β-lactam antibiotic.

### Claim 14 (depends on 1)

A metallo-β-lactamase inhibitor, comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1.
